Lim, Young-SukYoung-SukLimChan, Henry L YHenry L YChanAhn, Sang HoonSang HoonAhnSeto, Wai KayWai KaySetoNing, QinQinNingAgarwal, KoshKoshAgarwalJanssen, Harry L AHarry L AJanssenPan, Calvin QCalvin QPanChuang, Wan LongWan LongChuangIzumi, NamikiNamikiIzumiFung, ScottScottFungShalimar, nullnullShalimarBrunetto, MauriziaMauriziaBrunettoHui, Aric JosunAric JosunHuiChang, Ting-TsungTing-TsungChangLim, Seng GeeSeng GeeLimAbramov, FridaFridaAbramovFlaherty, John FJohn FFlahertyWang, HongyuanHongyuanWangYee, Leland JLeland JYeeJIA-HORNG KAOGane, EdwardEdwardGaneHou, JinlinJinlinHouButi, MariaMariaButi2024-01-122024-01-122023-1025895559https://scholars.lib.ntu.edu.tw/handle/123456789/638408Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB.enREACH-B; aMAP; antiviral therapy; incidence; mPAGE-B[SDGs]SDG3journal article10.1016/j.jhepr.2023.100847377715462-s2.0-85172927447https://api.elsevier.com/content/abstract/scopus_id/85172927447